Valuation: Inhalation Sciences Sweden AB

Market Cap 11.42M 1.18M 1.04M 956K 883K 1.67M 113M 1.7M 4.48M 55.65M 4.45M 4.35M 191M P/E 2024
-12.8x
P/E 2025 -12.4x
Enterprise Value 8.59M 891K 779K 719K 664K 1.26M 84.95M 1.28M 3.37M 41.85M 3.34M 3.27M 144M EV / Sales 2024
5.6x
EV / Sales 2025 55x
Free-Float
94.25%
Yield 2024 *
-
Yield 2025 -
1 day+5.69%
1 week-5.51%
Current month-4.70%
1 month+14.36%
3 months-9.35%
6 months-53.54%
Current year-94.86%
1 week 0.2
Extreme 0.2
0.24
1 month 0.19
Extreme 0.194
0.25
Current year 0.17
Extreme 0.172
0.58
1 year 0.17
Extreme 0.172
0.58
3 years 0.17
Extreme 0.172
4.99
5 years 0.17
Extreme 0.172
11.3
10 years 0.17
Extreme 0.172
15.48
Manager TitleAgeSince
Chief Executive Officer - 2019-09-15
Chief Tech/Sci/R&D Officer - 2004-12-31
Corporate Officer/Principal - 2025-06-01
Director TitleAgeSince
Director/Board Member - 2004-12-31
Director/Board Member - 2022-08-31
Director/Board Member - 2024-08-31
Change 5-day change 1-year change 3-year change Capi.($)
+5.69%-5.51%-94.86%-92.09% 1.18M
+0.48%+2.28%+24.46%+0.52% 196B
+0.68%-4.68%-20.11%+18.91% 144B
+0.16%+3.19%+1.04%-16.34% 141B
-0.49%+1.10%-56.78%-14.59% 66.54B
-0.20%-2.74%+18.26%-0.55% 53.09B
+2.41%+2.24%-22.46%-30.35% 44.12B
-0.31%+2.35%+11.31%+11.99% 37.93B
+0.11%-1.08%+23.21%+39.19% 36.96B
+1.24%+1.47%-11.63%-19.18% 29.43B
Average +0.95%-1.39%-12.76%-10.25% 74.89B
Weighted average by Cap. +0.39%-0.83%-1.09%-0.63%

Financials

2024 2025
Net sales 11.05M 1.15M 1M 925K 854K 1.62M 109M 1.65M 4.34M 53.84M 4.3M 4.21M 185M 3.04M 315K 276K 255K 235K 446K 30.09M 454K 1.19M 14.82M 1.18M 1.16M 50.95M
Net income -5.15M -534K -467K -431K -398K -755K -50.92M -768K -2.02M -25.09M -2M -1.96M -86.24M -10.16M -1.05M -922K -850K -785K -1.49M -101M -1.52M -3.99M -49.52M -3.96M -3.87M -170M
Net Debt -4M -415K -363K -335K -309K -587K -39.6M -597K -1.57M -19.51M -1.56M -1.53M -67.07M -2.83M -294K -257K -237K -219K -415K -28.01M -422K -1.11M -13.8M -1.1M -1.08M -47.44M
Logo Inhalation Sciences Sweden AB
Inhalation Sciences Sweden AB is a Sweden-based company, which develops and sells labtech equipment for inhalation research. The Company’s primary product is PreciseInhale, which is a laboratory system that lets scientists measure how inhaled particles act in lungs and affect human health. PreciseInhale is a dry powder aerosol research and development system, which generate aerosols and data of a quality. The system helps to eliminate poor candidate drugs before clinical trials. The secondary product is LaminarPace, a tool for drying small amounts of drug substance. The Company’s customers comprise Dow Chemical Group, Kings College London and Karolinska Institutet, among others. The Company’s main shareholder is Nordnet Pensionsforsakring.
Employees
5
Date Price Change Volume
26-07-10 SEK 0.2230 +5.69% 7,309
26-07-09 SEK 0.2110 -9.44% 68,090
26-07-08 SEK 0.2330 -4.90% 15,679
26-07-07 SEK 0.2450 +2.08% 925
26-07-06 SEK 0.2400 +1.69% 184,091

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ISAB Stock